Lumena Pharmaceuticals has started a global clinical programme to evaluate its drug candidate LUM001 in children with Alagille syndrome (ALGS).
The company has dosed the first patient in the IMAGO Phase II study, which is being conducted in the UK.
Go deeper with GlobalData
Enrolment of paediatric patients is anticipated to start later in 2013 in the ITCH Phase II study in the US.
Under theUK-based study, the company will enroll children, two years of age and older, with ALGS.
Lumena said ALGS is a rare form of cholestatic liver disease that results in impaired bile acid flow and retention of bile acids in the liver, leading to progressive liver damage that can cause liver failure.
As per the clinical programme, the company will evaluate LUM001’s ability to lower serum bile acids and alleviate severe itching.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataLUM001 is expected to offer a novel therapeutic approach to prevent bile acid mediated liver damage and alleviate severe itching by reducing serum bile acids with a once-daily oral solution.
IMAGO study principal investigator and paediatric hepatologist Alastair Baker said symptoms of Alagille syndrome include intense itching and sleep disruption on an ongoing basis, which will be a problem for the entire family when a child is suffering
“Pediatric patients have very little relief from the aggravating symptoms, and the need for treatment options is pressing,” Baker said.
Lumena is planning to start Phase II studies of LUM001 in adults with primary biliary cirrhosis (PBC), children with progressive familial intrahepatic cholestasis (PFIC), and in patients with primary sclerosing cholangitis (PSC) in late 2013.
The company has previously obtained orphan drug designation from the US Food & Drug Administration (FDA) Office of Orphan Product Development for LUM001.
The ITCH study is a multi-centre US-based study conducted on paediatric patients, two years of age and older, with ALGS.
The study is being conducted in collaboration with the Childhood Liver Disease Research and Education Network (ChiLDREN), a collaborative research network supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a part of the National Institutes of Health (NIH),which has a cooperative research and development agreement (CRADA) with Lumena.
Lumena and ChiLDREN are also collaborating with European investigators to evaluate LUM001 in patients with progressive familial intrahepatic cholestasis (PFIC), another rare cholestatic liver disease.
The ITCH study is anticipated to start later in 2013.
Image: ALGS is a rare form of cholestatic liver disease that results in impaired bile acid flow. Photo: courtesy of FreeDigitalPhotos.net.
